Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Autolus Therapeutics plcNASDAQ: AUTL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $24.57M rose 36.9% year over year, ahead of the -34.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 2.9% from the prior quarter.

Context

  • Cost of revenue amounted to 127.8% of revenue in FY2025, down 1265.6 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +36.9% holds above the trailing-twelve-month pace of -34.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.57M-2.9% QoQ
Last fiscal yearDec 2025
$96.59M-31.5% YoY
LTMMar 2026
$102.95M-34.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.9%——
1 year-31.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
96.59M USD
Year-over-year change
-31.5%

Cost of Revenue vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 cost of revenue of $102.95M is the 2nd highest of the 10 companies compared; the peer median is $12.33M.
  • Its year-over-year change of -34.6% is the 4th highest of 7, against a peer median of -42.9%.
  • Cost of revenue amounts to 111.2% of revenue for AUTL, versus a peer median of 18.1%.
AUTL Competitors Peer median
Cost of Revenue for AUTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M +63.0%+84.1%43.0%
AUTLAutolus Therapeutics plcLTM Mar 2026$102.95M -34.6%—111.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M -23.8%-4.7%—
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M -62.0%-2.1%515.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$29.86M ———
CLLSCellectis S.A.LTM Mar 2026$12.33M +39.3%+4.9%18.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M ——7522.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$1.95M -96.9%+0.0%17.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$1.37M ——3.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$897K -97.7%-57.2%3.9%
Peer median (excluding AUTL) $12.33M-42.9%-1.0%18.1%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.